The purpose of the report is to illustrate the state of the market of Blood Processing Devices and Consumables, to present actual information about the volumes of production, exports, imports, consumption and the state of the market, the changes that took place in 2017, and also, to build a forecast for the growth of the industry in the medium term until 2026. [Continue Reading]
The CAR T-cell therapy market is driven by factors such as rising prevalence of cancer, growing research in the immune-oncology, and massive funding from government health institution and pharma giants in CAR-T cell therapy development. The diagnosis of acute ALL is very ambiguous as the symptoms overlap with Non-Hodgkin lymphoma. World Health Organization guidelines have postulated that acute lymphocytic leukemia can be prevented up to a certain extent by prohibiting the exposure to radiation, chemical, viral infection, cigarette smoking and prolonged exposure to gasoline and electromagnetic fields. The traditional approach adopted for the treatment of leukemia was blood transfusion to increase the count of healthy blood cells, antibiotics used to curb the spread of infection and chemotherapy to kill the leukemia cells present in the bone marrow. However, advances in the cell therapy and gene therapy has have rendered the development of oncology treatment by body’s own immune system. The FDA approved CAR T-cell therapy are Axicabtagene ciloleucel (Yescarta) and Tisagenleucel (Kymriah),). Currently CD19 antigens have been approved by USFDA for the treatment of relapsed b-cell acute lymphocytic leukemia. Whereas, there are more than 2,000 candidates in the clinical trials for different cancer indications…..
Leading Players: Gilead Sciences, Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Celgene Corporation, Cellectis, Kite Pharma, Eureka Therapeutics, Juno Therapeutics, Sorrento Therapeutics and Novartis AG among others.
Browse here for full report with Toc: https://www.credenceresearch.com/report/car-t-cell-therapy-market
Why was the report written?
This report is the result of an extensive survey drawn from Credence Research’s exclusive panel of leading global market industry executives; it provides data and analysis on buyer investment, acquisition, and developments within the global market research. It includes key topics such as global CAR T-Cell Therapy buyer expenditure and procurement behaviors and strategies and recognizes the threats and possibilities within the industry, economic outlook trends, and business confidence within global industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives’ attitude and changing behaviors, creating a gap in presenting the business outlook of the industry; in an effort to bridge this gap, Credence Research created this primary research-based report by gathering the opinions of multiple stakeholders in the value chain of the global industry. [Continue Reading]
What is the current market landscape and what is changing?
Executives from the global industry anticipate an increase in levels of consolidation, with 55% of respondents projecting an increase in merger and acquisition (M&A) activities in 2017.
The report on the market of CAR T-Cell Therapy contains:
Analysis and forecast of CAR T-Cell Therapy market dynamics;
Analysis of domestic production, market shares of the main market players;
Analysis of exports and imports;
Analysis of factors, leading the development of the CAR T-Cell Therapy market;
Assessment and forecast of CAR T-Cell Therapy market development;
Financial and business profiles of the leading companies in theCAR T-Cell Therapy industry.
– Up to date working CAR T-Cell Therapy data by major regions in the world, the forecast of planned capacity additions by 2026
– The annual breakdown of capital expenditure spending on proposed CAR T-Cell Therapy for the period 2018 to 2026
– Planned CAR T-Cell Therapy additions and capital expenditure spending by key countries and companies across the world
– Planned capital expenditure spending on new CAR T-Cell Therapy projects by region, key countries, and companies
– Details of major planned CAR T-Cell Therapy projects in the world up to 2026
Browse here for full report with Toc:https://www.credenceresearch.com/report/car-t-cell-therapy-market
Also you can request us for sample in pdf with more details and graph:https://www.credenceresearch.com/sample-request/58970
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Credence Research Inc.
105 N 1st ST #429
Toll Free (US/CANADA): +1-800-361-8290